Paris, France
Paris, France

Time filter

Source Type

WiseGuyReports.Com Publish a New Market Research Report On – “Immunotherapy Drugs Market Global Potential Growth,Share,Demand and Analysis Of Key Players Research Report Forecasts to 2020”. This market research report presents a comprehensive segmentation of the global immunotherapy drugs market by type of immunotherapy (mAbs, vaccines, immune checkpoint inhibitors, non-specific immunotherapies, and others), by therapy area (oncology, infectious disease, autoimmune and inflammatory disorders, respiratory diseases, and others), and by geography (the Americas, APAC, and EMEA). Key vendors are AbbVie, Amgen, Bristol-Myers Squibb, F.Hoffmann-La Roche, Johnson & Johnson, and Merck. Overview of the global immunotherapy drugs market  The market research analyst predicts that the global immunotherapy drugs market will grow at a steady CAGR of close to 12% by 2020. During a rise in cancer and a number of autoimmune diseases, the need for immunotherapy drugs is on the rise. Furthermore, with the increasing demand for mAbs, the market for immunotherapy drugs will have a positive outlook until the end of the forecast period. mAbs have a high affinity for specific disease cells and areas that need treatment. Consequently, they can be used for therapies like radioimmunotherapy and antibody-directed enzyme prodrug therapy. The augmented usage of these antibodies in drug development will help to bolster the market’s revenue generating capacity over the course of the next four years. For more information or any query mail at [email protected] An important factor impelling the prospects for growth in this market is the emergence of biosimilars. Unlike generic drugs, which have active pharmaceutical ingredients similar to original drugs, biosimilars are almost identical to their originator biologic compounds. Since biosimilars help to make treatments more accessible to patients and are less expensive than biologics, their sale among the end users is anticipated to increase significantly over the next few years. Segmentation by type of immunotherapy and analysis of the immunotherapy drugs market  - mAbs  - Vaccines  - Immune checkpoint inhibitors  - Non-specific immunotherapies During 2015, the mAbs segment dominated this market and accounted for an impressive market share of nearly 61%. The development of new drugs and the entry of new molecules like zanolimumab, elotuzumab, obinutuzumab, and onartuzumab into the market will aid in the growth of this market segment during the forecast period. Geographical segmentation and analysis of the immunotherapy drugs market  - Americas  - APAC  - EMEA The Americas dominated the global market with over 50% market share in 2015. The market is flourishing in this region due to the higher incidences of cancer, infectious diseases, and autoimmune diseases in the US. Additionally, factors such as the high affordability of therapies due to the presence of well-structured reimbursement plans will also spur the prospects for market growth until 2020. Competitive landscape and key vendors  The global market for immunotherapy drugs is highly competitive due to the presence of a number of large and small vendors. Many of these vendors have a huge global presence and enter into strategic alliances to aid in the manufacture and marketing of essential drugs. Safety and effectiveness of drugs are key factors, which will give vendors an edge in the marketplace. Key vendors in this market are - AbbVie  Amgen  Bristol-Myers Squibb  F.Hoffmann-La Roche  Johnson & Johnson  Merck  Other prominent vendors are AB Science. Ablynx, Acorda Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys, Agenus, Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma, Antigen Express, Argos Therapeutics, Astellas Pharma, AstraZeneca, AVAX Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical, Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus BioSciences, CTI BioPharma, CureVac, Daiichi Sankyo, Eisai, Eli Lilly, Fortress Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune, Gradalis, Heat Biologics, Hospira, Idera, Inmatics, ImmunoCellular Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals, Oncothyreon, Oncovir, Opexa Therapeutics, Oxford BioMedica, Pfizer, Prima BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz, Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech, Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, and XBiotech. Key questions answered in the report include  - What will the market size and the growth rate be in 2020?  - What are the key factors driving the global immunotherapy drugs market?  - What are the key market trends impacting the growth of the global immunotherapy drugs market?  - What are the challenges to market growth for immunotherapy drugs?  - Who are the key vendors in the global immunotherapy drugs market?  - What are the market opportunities and threats faced by the vendors in the immunotherapy drugs market?  - Trending factors influencing the market shares of the Americas, APAC, and EMEA.  - What are the key outcomes of the five forces analysis of the global immunotherapy drugs market? For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Kotsakis A.,University of Crete | Vetsika E.-K.,University of Crete | Christou S.,University of Crete | Hatzidaki D.,University of Crete | And 8 more authors.
Annals of Oncology | Year: 2012

Background: TERT (telomerase reverse transcriptase) plays a critical role in tumor cell growth and survival. In an expanded phase II study, we evaluated the immunological and clinical responses to the TERT-targeting Vx-001 vaccine in patients with advanced solid tumors. Methods: HLA-A*0201-positive patients received two subcutaneous injections of the optimized TERT. 572Y peptide followed by four injections of the native TERT. 572 peptide, every 3 weeks. Peptide-specific immune responses were evaluated by enzyme-linked immunosorbent spot at baseline, and after the second and the sixth vaccinations. Results: Fifty-five patients were enrolled and 34 (62%) completed the six vaccinations. A TERT-specific T-cell immune response was observed in 55% and 70% of patients after the second and the sixth vaccinations, respectively. The disease control rate (DCR) was 36% [95% confidence interval (CI) 24% to 49%], including one complete and one partial response. Immunologically responding patients had a better clinical outcome than non responders [DCR: 44% versus 14% (P = 0.047); progression-free survival (PFS): 5.2 versus 2.2 months (P = 0.0001) and overall survival: 20 versus 10 months (P = 0.041)]. Multivariate analysis revealed that the immunological response was an independent variable associated with increased PFS (hazard ratio = 3.35; 95% CI 1.7-6.7). Conclusion: Vx-001 vaccine was well tolerated and induced a TERT-specific immunological response, which was significantly correlated with improved clinical outcome. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Vetsika E.-K.,University of Crete | Konsolakis G.,University of Crete | Aggouraki D.,University of Crete | Kotsakis A.,University of Crete | And 7 more authors.
Cancer Immunology, Immunotherapy | Year: 2012

Vx-001, an HLA-A*0201 restricted telomerase (TERT)-specific anti-tumor vaccine, is composed of the 9-mer cryptic TERT 572 peptide and its optimized variant TERT 572Y. We have previously shown that Vx-001 is non-toxic, highly immunogenic and in vaccinated NSCLC patients early specific immune response is associated with prolonged survival. The aim of the present study was to investigate the specific T-cell immune response against Vx-001. Fifty-five patients with chemo-resistant advanced solid tumors were vaccinated with TERT 572Y (2 subcutaneous injections) followed by TERT 572 peptide (4 subcutaneous injections) every 3 weeks. Specific immune response was evaluated by IFN-γ and perforin ELISpot and intracellular cytokine staining assays. TERT-reactive T cells were detected in 27 (51%) out of 53 evaluable patients after the 2nd vaccination and in 22 (69%) out of 32 evaluable patients after the completion of 6 vaccinations. Immune responses developed irrespective of the stage of disease and disease status before vaccination. Patients with disease progression at study entry who developed a post-vaccination-induced immunological response had a significant overall survival benefit compared to the post-vaccination non-responders. The Vx-001 vaccine is a promising candidate for cancer immunotherapy since it can induce a TERT-specific T-cell immune response that is associated with prolonged survival. © 2011 Springer-Verlag.

Gallou C.,Vaxon Biotech | Rougeot A.,Vaxon Biotech | Graff-Dubois S.,French Institute of Health and Medical Research | Kosmatopoulos K.,Vaxon Biotech | Menez-Jamet J.,Vaxon Biotech
Oncotarget | Year: 2016

Tumor Associated Antigens (TAAs) are the privileged targets of almost all the cancer vaccines tested to date. Unfortunately all these vaccines failed to show a clinical efficacy. The main reason for this failure is the immune tolerance to TAAs that are self-proteins expressed by normal and cancer cells. Self-tolerance to TAAs is directed against their dominant rather than against their cryptic epitopes. The best way to overcome self-tolerance to TAAs would therefore be to target their cryptic epitopes. However, because of their low HLA-I affinity, cryptic peptides are nonimmunogenic and cannot be used to stimulate an antitumor immune response unless their immunogenicity has been previously enhanced. In this paper we describe a general approach to enhance immunogenicity of almost all the HLA-B*0702 restricted cryptic peptides derived from TAAs. It consists in substituting residues at position 1 or 9 of low HLA-B*0702 affinity cryptic peptides by an Alanine or a Leucine respectively. These substitutions increase affinity of peptides for HLA-B*0702. These optimized cryptic peptides are strongly immunogenic and very importantly CTL they stimulate recognize their native counterparts. TAAs derived optimized cryptic peptides can be considered as universal antitumor vaccine since they escape self-tolerance, are immunogenic and are not patient specific.

Kosmatopoulos K.,Vaxon Biotech
Oncogene | Year: 2016

Tumors use several strategies to evade the host immune response, including creation of an immune-suppressive and hostile tumor environment. Tissue hypoxia due to inadequate blood supply is reported to develop very early during tumor establishment. Hypoxic stress has a strong impact on tumor cell biology. In particular, tissue hypoxia contributes to therapeutic resistance, heterogeneity and progression. It also interferes with immune plasticity, promotes the differentiation and expansion of immune-suppressive stromal cells, and remodels the metabolic landscape to support immune privilege. Therefore, tissue hypoxia has been regarded as a central factor for tumor aggressiveness and metastasis. In this regard, manipulating host–tumor interactions in the context of the hypoxic tumor microenvironment may be important in preventing or reverting malignant conversion. We will discuss how tumor microenvironment-driven transient compositional tumor heterogeneity involves hypoxic stress. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of conventional therapies as well as cancer immunotherapy. Thus, understanding how tumor and stromal cells respond to hypoxia will allow for the design of innovative cancer therapies that can overcome these barriers. A better understanding of hypoxia-dependent mechanisms involved in the regulation of immune tolerance could lead to new strategies to enhance antitumor immunity. Therefore, discovery and validation of therapeutic targets derived from the hypoxic tumor microenvironment is of major importance. In this context, critical hypoxia-associated pathways are attractive targets for immunotherapy of cancer. In this review, we summarize current knowledge regarding the molecular mechanisms induced by tumor cell hypoxia with a special emphasis on therapeutic resistance and immune suppression. We emphasize mechanisms of manipulating hypoxic stress and its associated pathways, which may support the development of more durable and successful cancer immunotherapy approaches in the future.Oncogene advance online publication, 27 June 2016; doi:10.1038/onc.2016.225. © 2016 Macmillan Publishers Limited

The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a medicinal composition, for selecting and/or boosting part of a CTL immune response which has been initiated by an optimized immunogenic peptide derived from said native peptide. The invention also concerns vaccination kits which comprise several doses of optimized peptides and of their cognate native peptides.

The present invention relates to a method for preparing a vaccine formulation with an optimized polypeptide comprising three epitopes and Montanide as adjuvant, for use in anti-cancer immunotherapy for administration to a human subject.

The invention provides methods for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*0702-restricted cryptic epitopes. The HLA-B*0702-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*0702-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*0702 phenotype.

The invention pertains to an optimized chimeric polypeptide for use in HLA-B7 cancer patients, which comprises four optimized peptides derived from cryptic tumor epitopes (CEA, TERT, MAGE and HER-2/neu) to enhance their immunogenicity.

The present invention relates to a method for preparing a vaccine formulation with an optimized polypeptide comprising three epitopes and MONTANIDE as adjuvant, for use in anti-cancer immunotherapy for administration to a human subject.

Loading Vaxon Biotech collaborators
Loading Vaxon Biotech collaborators